PRAME, or preferentially expressed antigen in melanoma, was originally identified as a gene encoding a HLA-A24 restricted antigenic peptide presented to autologous tumour-specific cytotoxic T lymphocytes derived from a patient with melanoma [1]. The gene discussed is PRAME; the disease is neoplasm.